Philip Scheltens, MD, PhD, discusses the use and results of imaging and fluid biomarkers in the patient case study. Marwan Sabbagh, MD, then describes the value and use of biomarkers in the diagnosis of Alzheimer’s disease (including imaging and CSF biomarkers), particularly for differential diagnosis across dementia etiologies.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.